Lead program BE-101 for Hemophilia B enters the clinic, and second development candidate BE-102 is unveiled.
Organizations Involved
Seattle Children's Research Institute
Company Description
Be Biopharma is a leader in the discovery and development of engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions.
Market
Healthcare
Location
Cambridge,
MA,
USA
Coinvestors
ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures